Bradley Monk, MD, FACOG, FACS, discusses the mechanism of action of VB-111 in patients with ovarian cancer.
Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, discusses the mechanism of action of VB-111 in patients with ovarian cancer.
VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels, according to Monk.
The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.